Recite me link

All questions are shown as received by the Trust.
Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. Atezolizumab (Tecentriq)
b. Durvalumab (Imfinzi)
c. Nivolumab (Opdivo)
d. Pembrolizumab (Keytruda)
e. Chemotherapy
f. Radiotherapy
g. Chemotherapy AND Radiotherapy
h. Osimertinib
Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
h. Zolbetuximab (Vyloy)

Treatment of certain types of cancer. 291124.docx